{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:01:05Z","timestamp":1784955665538,"version":"3.55.0"},"reference-count":195,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer immunotherapy has revolutionized cancer treatment over the past decades, offering renewed hope to patients with previously untreatable malignancies. This therapeutic approach could be categorized into three primary strategies: immune checkpoint blockade, adoptive cell therapy, and cancer vaccines. Immune checkpoint inhibitors have been highly successful in boosting anti-tumour immune responses by blocking the immunosuppressive signals that cancer cells exploit to evade immune surveillance, mainly that exerted by cytotoxic T lymphocytes. Adoptive cell therapy, particularly chimeric antigen receptor (CAR)-T cell therapy, involves the infusion of genetically modified cytotoxic T cells to specifically target tumour cells, showing particular efficacy in hematological malignancies. Cancer vaccines have also emerged as a promising strategy, eliciting anti-tumour responses via the patient\u2019s own immune system. Despite these advancements, several challenges persist, particularly in the treatment of solid tumours. These include the development of tumour resistance, off-target effects that lead to adverse side effects, manufacturing complications, and variability in patient clinical outcomes. Overcoming these limitations will require further research and innovation to optimize the clinical translation of immunotherapy and broaden its application toward more personalized medicine. This review highlights the advancements and key challenges in the mentioned cancer immunotherapy strategies, with a special emphasis on the reinforcement of adaptive immune system against tumour cells. Additionally, some alternative approaches relying on the modulation of innate immune system are also summarized.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1697505","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:20:31Z","timestamp":1768206031000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The broad spectrum of cancer and immunotherapy: achievements and limitations"],"prefix":"10.3389","volume":"16","author":[{"given":"Arifa","family":"Aman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Gonz\u00e1lez-Titos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Picon-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Hern\u00e1ndez-Camarero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/path.2865","article-title":"Revisiting cancer immunoediting by understanding cancer immune complexity","volume":"224","author":"Manjili","year":"2011","journal-title":"J Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2022.117376","article-title":"Cancer immunoediting hypothesis: history, clinical implications and controversies","volume":"47","author":"Lasek","year":"2022","journal-title":"Cent-Eur J Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2017-ct069","article-title":"Abstract CT069: Keynote-355: Randomized, double-blind, phase III study of Pembrolizumab Plus Chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)","volume":"77","author":"Cortes","year":"2017","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21417\/rp2024nm","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1\/2 trial","author":"Yarchoan","year":"2024","journal-title":"immuneACCESS"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840207","article-title":"Patterns of peripheral blood B-Cell subtypes are Associated with Treatment response in patients treated with Immune Checkpoint inhibitors: a prospective longitudinal Pan-cancer Study","volume":"13","author":"Barth","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre single-arm phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-cd19 car T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-023-01378-3","article-title":"Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours","volume":"18","author":"Chen","year":"2023","journal-title":"Nat Nanotechnol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: Current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000940","article-title":"In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy","volume":"8","author":"Cheng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-024-00120-3","article-title":"A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration","volume":"3","author":"Oyama","year":"2025","journal-title":"BJC Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190801","article-title":"Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses","volume":"216","author":"Jiang","year":"2019","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14670\/HH-18-587","article-title":"Decreased survival in patients with pancreatic cancer may be associated with an increase in histopathological expression of inflammasome marker NLRP3","volume":"39","author":"Fraile-Martinez","year":"2024","journal-title":"Histol Histopathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2017.11.010","article-title":"Decreased NLRP3 inflammasome expression in aged lung may contribute to increased susceptibility to secondary streptococcus pneumoniae infection","volume":"105","author":"Cho","year":"2018","journal-title":"Exp Gerontol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1038\/s41467-021-26112-2","article-title":"Hu, Z. et\u00a0al. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance","volume":"12","author":"Cao","year":"2021","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J Virol"},{"key":"B21","article-title":"2015 European cancer congress","author":"Long","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2016-0021","article-title":"Talimogene Laherparepvec: Overview, combination therapy and current practices","volume":"3","author":"O\u2019Donoghue","year":"2016","journal-title":"Melanoma Management"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202409835","article-title":"Improved efficacy of triple-negative breast cancer immunotherapy via hydrogel-based co-delivery of CAR-T cells and mitophagy agonist","volume":"2409835","author":"Li","year":"2025","journal-title":"Advanced Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333617","article-title":"CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases","volume":"74","author":"Li","year":"2025","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.c.7851710","article-title":"Mutation of SMARCA4 induces cancer cell-intrinsic defects in the enhancer landscape and resistance to immunotherapy","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ccell.2025.01.009","article-title":"Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma","volume":"43","author":"Schiantarelli","year":"2025","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06231-0","article-title":"B-cell specific checkpoint molecules that regulate anti-tumour immunity","volume":"619","author":"Bod","year":"2023","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298571","article-title":"The role of immune checkpoints in antitumour response: a potential antitumour immunotherapy","volume":"14","author":"Mej\u00eda-Guarnizo","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad144","article-title":"Adoptive cell immunotherapy for breast cancer: Harnessing the power of immune cells","volume":"115","author":"Li","year":"2023","journal-title":"J Leukocyte Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1038\/s41467-022-35469-x","article-title":"PRDM1\/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2025.05.003","article-title":"The potential application of stroma modulation in targeting tumor cells: Focus on pancreatic cancer and breast cancer models","author":"Roscigno","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.02.016","article-title":"Multi-omics analysis reveals the unique landscape of DLD in the breast cancer tumour microenvironment and its implications for immune-related prognosis","volume":"23","author":"Xu","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.4c00266","article-title":"AUNP-12 near-infrared fluorescence probes across NIR-I to Nir-II enable in vivo detection of PD-1\/PD-L1 axis in the tumor microenvironment","volume":"35","author":"Zhang","year":"2024","journal-title":"Bioconjugate Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"101892","DOI":"10.1016\/j.tranon.2024.101892","article-title":"Peptide-based inhibitors targeting the PD-1\/PD-L1 axis: potential immunotherapeutics for cancer","volume":"42","author":"Bojko","year":"2024","journal-title":"Transl Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.752065","article-title":"Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced development","volume":"13","author":"Sasikumar","year":"2022","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0060","article-title":"A phase I\/II clinical trial of pembrolizumab and cabozantinib in metastatic renal cell carcinoma","volume":"3","author":"Kessler","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008325","article-title":"High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma","volume":"12","author":"Rischin","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"pkae030","DOI":"10.1093\/jncics\/pkae030","article-title":"Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations","volume":"8","author":"Necchi","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"103461","DOI":"10.1016\/j.esmoop.2024.103461","article-title":"First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study","volume":"9","author":"D\u2019Angelo","year":"2024","journal-title":"ESMO Open"},{"key":"B45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.3390\/ijms24076710","article-title":"The efficacy of tumour mutation burden as a biomarker of response to immune checkpoint inhibitors","volume":"24","author":"Moeckel","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00092","article-title":"Tumour mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness","volume":"7","author":"Quintanilha","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumour mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"B49","doi-asserted-by":"publisher","first-page":"15576","DOI":"10.3390\/ijms232415576","article-title":"Dual role of fibroblasts educated by tumour in cancer behavior and therapeutic perspectives","volume":"23","author":"Toledo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1039631","article-title":"Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343450","article-title":"Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non\u2013small cell lung cancer","volume":"15","author":"Xin","year":"2024","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15303","article-title":"Gut microbiome affects the response to immunotherapy in non-small cell lung cancer","volume":"15","author":"Ren","year":"2024","journal-title":"Thorac Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007959","article-title":"Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1\/PD-L1 inhibitors","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346687","article-title":"Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors","volume":"15","author":"Morelli","year":"2024","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad229","article-title":"Focus on immune checkpoint inhibitors-related intestinal inflammation: from pathogenesis to therapeutical approach","volume":"30","author":"Del Gaudio","year":"2024","journal-title":"Inflammation Bowel Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008078","article-title":"Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis","volume":"12","author":"Gudd","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1366691","article-title":"Endocrine system-related adverse events associated with PD-1\/PD-L1 inhibitors: data mining from the FDA adverse event reporting system","volume":"11","author":"Shi","year":"2024","journal-title":"Front Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s13256-023-04162-y","article-title":"Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report","volume":"17","author":"Leow","year":"2023","journal-title":"J Med Case Rep"},{"key":"B60","unstructured":"Supportive and palliative care | ESMO"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/cancers16071340","article-title":"Early serum markers for immune checkpoint inhibitor induced hypophysitis in melanoma patients","volume":"16","author":"Mitri","year":"2024","journal-title":"Cancers"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-258706","article-title":"Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound","volume":"17","author":"Harnden","year":"2024","journal-title":"BMJ Case Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","article-title":"A membrane-associated MHC-I inhibitory axis for cancer immune evasion","volume":"186","author":"Chen","year":"2023","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/vaccines12040397","article-title":"Case report: long-term survival of a patient with cerebral metastasized ovarian carcinoma treated with a personalized peptide vaccine and anti-PD-1 therapy","volume":"12","author":"Zelba","year":"2024","journal-title":"Vaccines"},{"key":"B65","doi-asserted-by":"publisher","first-page":"19154","DOI":"10.1038\/s41598-023-46466-5","article-title":"Characterization of the genomic alterations in poorly differentiated thyroid cancer","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/neuonc\/noad248","article-title":"The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis","volume":"26","author":"de Sauvage","year":"2024","journal-title":"Neuro-Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00262-023-03516-4","article-title":"Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.019","article-title":"EGFR oncogenic mutations in NSCLC impair macrophage phagocytosis and mediate innate immune evasion through up-regulation of CD47","volume":"19","author":"Hu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","article-title":"IGSF8 is an innate immune checkpoint and cancer immunotherapy target","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-102419-035900","article-title":"Siglecs as immune cell checkpoints in disease","volume":"38","author":"Duan","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180282","article-title":"Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer","volume":"134","author":"Wen","year":"2024","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anticolony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107126","article-title":"CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer","volume":"196","author":"Lv","year":"2024","journal-title":"Pharmacol Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.05.001","article-title":"Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective fc\u03b3R engagement","volume":"29","author":"Rony","year":"2016","journal-title":"Cancer Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"43","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010565","article-title":"First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer","volume":"13","author":"Lakhani","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115319","article-title":"From molecular precision to clinical practice: A comprehensive review of bispecific and trispecific antibodies in hematologic Malignancies","volume":"26","author":"Amoozgar","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"Lancet Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030027","article-title":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.pdf","author":"Pillarisetti","year":"2024","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2023-008295","article-title":"Bispecific immune cell engager enhances the anticancer activity of CD16 + NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice","volume":"12","author":"Nikkhoi","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815515116","article-title":"Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/vaccines10030457","article-title":"Genetic modification of T cells for the immunotherapy of cancer","volume":"10","author":"Quinn","year":"2022","journal-title":"Vaccines"},{"key":"B86","doi-asserted-by":"publisher","first-page":"20210058","DOI":"10.1002\/EXP.20210058","article-title":"Adoptive cell therapy for cancer treatment","volume":"3","author":"Du","year":"2023","journal-title":"Exploration"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389018","article-title":"Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization","volume":"15","author":"Hanssens","year":"2024","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3390\/biomedicines11102805","article-title":"TCR-engineered lymphocytes targeting NY-ESO-1: in vitro assessment of cytotoxicity against tumours","volume":"11","author":"Alsalloum","year":"2023","journal-title":"Biomedicines"},{"key":"B89","doi-asserted-by":"publisher","first-page":"102268","DOI":"10.1016\/j.eclinm.2023.102268","article-title":"Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns","volume":"65","author":"Barsan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.54","article-title":"Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study","volume":"8","author":"Berning","year":"2024","journal-title":"HemaSphere"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009072","article-title":"Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia","volume":"7","author":"Chen","year":"2023","journal-title":"Blood Adv"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023447","article-title":"Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.3390\/jcm12216883","article-title":"CAR T-cells for the treatment of B-cell acute lymphoblastic leukemia","volume":"12","author":"Saleh","year":"2023","journal-title":"J Clin Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B96","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother CII"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumour activity","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00262-024-03688-4","article-title":"Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma","volume":"73","author":"Stock","year":"2024","journal-title":"Cancer Immunol Immunother CII"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1857","article-title":"TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumours","volume":"10","author":"Nishimura","year":"2024","journal-title":"Sci Adv"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14103","article-title":"Tumour microenvironment and CAR-T cell immunotherapy in B-cell lymphoma","volume":"112","author":"Cai","year":"2024","journal-title":"Eur J Haematol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","article-title":"CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition","volume":"15","author":"Andreu-Saumell","year":"2024","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01216-4","article-title":"Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells","author":"Zhang","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second generation CAR T-Cells in advanced solid tumours","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008555","article-title":"Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system","volume":"12","author":"Khaniya","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","article-title":"A novel TanCAR targeting IL13R\u03b12 and EphA2 for enhanced glioblastoma therapy","volume":"24","author":"Muhammad","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J Exp Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1268698","article-title":"A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells","volume":"14","author":"Svec","year":"2023","journal-title":"Front Immunol"},{"key":"B109","article-title":"The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumours","volume":"152","author":"Gattenloehner","year":"1998","journal-title":"Am J Pathol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B111","doi-asserted-by":"publisher","first-page":"17588359231170474","DOI":"10.1177\/17588359231170474","article-title":"The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review","volume":"15","author":"Martin","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00404-2","article-title":"RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells","volume":"30","author":"Bouquet","year":"2023","journal-title":"Gene Ther"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","article-title":"Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting","volume":"14","author":"Ruffo","year":"2023","journal-title":"Nat Commun"},{"key":"B115","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.3390\/cancers15194844","article-title":"A novel allogeneic rituximab-conjugated gamma delta T cell therapy for the treatment of relapsed\/refractory B-cell lymphoma","volume":"15","author":"Li","year":"2023","journal-title":"Cancers"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumours: A phase 1 trial","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"Ebiomedicine"},{"key":"B119","volume-title":"171 Journal of Neuro-Oncology CAR-Engineered NK Cells versus CAR T Cells in Treatment of Glioblastoma; Strength and Flaws","author":"Sabahi","year":"2024"},{"key":"B120","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12885-025-13780-2","article-title":"CAR-NK cells with dual targeting of PD-L1 and MICA\/B in lung cancer tumour models","volume":"25","author":"Zhi","year":"2025","journal-title":"BMC Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1750100","article-title":"Oncogenicity of TCR-engineered T cells: considerations for successful clinical translation","volume":"20","author":"Raja","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1353","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c259T cells in synovial sarcoma","volume":"8","author":"D\u2019Angelo","year":"2018","journal-title":"Cancer Discov"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.013","article-title":"TCR-T cell therapy in solid tumors: challenges and opportunities","volume":"41","author":"Rosato","year":"2023","journal-title":"Cancer Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00645","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"41","author":"Sarnaik","year":"2023","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000159","article-title":"T-cell therapy for solid tumors","volume":"21","author":"Deniger","year":"2015","journal-title":"Cancer J"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0551","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts and hopes","volume":"25","author":"Rohaan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2184760","DOI":"10.1080\/21645515.2023.2184760","article-title":"Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials","volume":"19","author":"Goldstone","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00493-x","article-title":"Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry","volume":"25","author":"Wei","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002432","article-title":"In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumour immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumour models","volume":"9","author":"Oba","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.752563","article-title":"Case report: in situ vaccination by autologous CD16+ Dendritic cells and anti-PD-L 1 antibody synergized with radiotherapy to boost T cells-mediated antitumour efficacy in A psoriatic patient with cutaneous squamous cell carcinoma","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2308280","DOI":"10.1002\/advs.202308280","article-title":"rWTC-MBTA vaccine induces potent adaptive immune responses against glioblastomas via dynamic activation of dendritic cells","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2096363","DOI":"10.1080\/2162402X.2022.2096363","article-title":"Trial watch: Dendritic cell (DC)-based immunotherapy for cancer","volume":"11","author":"Laureano","year":"2022","journal-title":"Oncoimmunology"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353570","article-title":"The functional role of L-fucose on dendritic cell function and polarization","volume":"15","author":"Burton","year":"2024","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2213132","DOI":"10.1080\/2162402X.2023.2213132","article-title":"Augmented interferon regulatory factor 7 axis in whole tumour cell vaccines prevents tumour recurrence by inducing interferon gamma-secreting B cells","volume":"12","author":"Kajihara","year":"2023","journal-title":"Oncoimmunology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12967-022-03714-y","article-title":"Whole-cell tumour vaccines desialylated to uncover tumour antigenic Gal\/GalNAc epitopes elicit anti-tumour immunity","volume":"20","author":"Huang","year":"2022","journal-title":"J Transl Med"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3390\/cells11131986","article-title":"A therapeutic whole-tumour-cell vaccine covalently conjugated with a TLR7 agonist","volume":"11","author":"Chi","year":"2022","journal-title":"Cells"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302250","article-title":"Advanced oxidation nanoprocessing boosts immunogenicity of whole tumour cells","volume":"10","author":"Zhang","year":"2023","journal-title":"Adv Sci Weinh Baden-Wurtt Ger"},{"key":"B147","doi-asserted-by":"publisher","first-page":"122218","DOI":"10.1016\/j.biomaterials.2023.122218","article-title":"Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination","volume":"301","author":"He","year":"2023","journal-title":"Biomaterials"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202300019","article-title":"A multivalent personalized vaccine orchestrating two-signal activation rebuilds the bridge between innate and adaptive antitumour immunity","volume":"7","author":"Kou","year":"2023","journal-title":"Small Methods"},{"key":"B149","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13046-023-02744-8","article-title":"rWTC-MBTA: autologous vaccine prevents metastases via antitumour immune responses","volume":"42","author":"Ye","year":"2023","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2021.04.004","article-title":"Antitumour effects of iPSC-based cancer vaccine in pancreatic cancer","volume":"16","author":"Ouyang","year":"2021","journal-title":"Stem Cell Rep"},{"key":"B151","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.95","article-title":"Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumour antigens original from T-ALL-iPSC in vivo","volume":"3","author":"Li","year":"2024","journal-title":"Cancer Innov"},{"key":"B152","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/cancers15133328","article-title":"Anti-tumour efficacy of in situ vaccination using bacterial outer membrane vesicles","volume":"15","author":"Caproni","year":"2023","journal-title":"Cancers"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011589","article-title":"A clinical trial of therapeutic vaccination in lymphoma with serial tumour sampling and single-cell analysis","volume":"8","author":"Shree","year":"2024","journal-title":"Blood Adv"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.22092\/ari.2023.362496.2662","article-title":"Comparison of three different methods of transfection for the production of recombinant adenovirus expressing human carcinoembryonic antigen gene","volume":"78","author":"Yari","year":"2023","journal-title":"Arch Razi Inst"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.12.002","article-title":"A phase 2, double-blind, randomized controlled trial of PROSTVAC in prostate cancer patients on active surveillance","volume":"9","author":"Parsons","year":"2023","journal-title":"Eur Urol Focus"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers"},{"key":"B157","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: A phase Ib study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202404316","article-title":"Neoantigen-Displaying Protein Nanoparticles induce antitumor immunity in melanoma","volume":"2024","author":"Kim","year":"2025","journal-title":"Adv Healthc Mate"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.34133\/bmef.0038","article-title":"Design and evaluation of synthetic delivery formulations for peptide-based cancer vaccines","volume":"5","author":"Song","year":"2024","journal-title":"BME Front"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08347-6","article-title":"mRNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"626","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"B161","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of MRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J Pharm Sci"},{"key":"B162","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","article-title":"Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy","volume":"17","author":"Toledo","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness\u2014A literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24404","article-title":"Current status and future of cancer vaccines: A bibliographic study","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"B165","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"JCO"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02407-8","article-title":"Khanamir, R.A. et\u00a0al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.027","article-title":"Pan-cancer proteogenomics characterization of tumour immunity","volume":"187","author":"Petralia","year":"2024","journal-title":"Cell"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2319340","article-title":"Treatment resistance in pancreatic and biliary tract cancer: Molecular and clinical pharmacology perspectives","volume":"17","author":"Toledo","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumour microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003231","article-title":"Immuno-oncology trends: preclinical models, biomarkers, and clinical development","volume":"10","author":"Franklin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B172","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.annonc.2022.09.158","article-title":"Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022","volume":"34","author":"Araujo","year":"2023","journal-title":"Ann Oncol"},{"key":"B173","first-page":"20200014","article-title":"Big data and artificial intelligence in future patient management. How is it all started? Where are we at now? Quo tendimus","volume":"1","author":"Mina","year":"2020","journal-title":"Adv Lab Med"},{"key":"B174","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"Car T cell therapy for patients with solid tumours: Key lessons to learn and Unlearn","volume":"21","author":"Albelda","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0272","article-title":"The fate(s) of CAR T-cell therapy: navigating the risks of CAR+ T-cell Malignancy","volume":"5","author":"Abou-el-Enein","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B176","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-023-01799-7","article-title":"Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing","volume":"22","author":"Balke-Want","year":"2023","journal-title":"Mol Cancer"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401683","article-title":"Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR\/Cas9 editing and safety evaluation of the transcriptome","volume":"15","author":"Pavlovic","year":"2024","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1388475","article-title":"Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review","volume":"14","author":"Moradi","year":"2024","journal-title":"Front Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.12.011","article-title":"Immune evasion of dormant disseminated tumour cells is due to their scarcity and can be overcome by T cell immunotherapies","volume":"42","author":"Goddard","year":"2024","journal-title":"Cancer Cell"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B181","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel in relapsed or refractory multiple myeloma","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B185","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Toxicities of CAR T-cell therapy","volume":"13","author":"Brudno","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06082-4","article-title":"mRNA-4157\/V940 plus pembrolizumab in melanoma","volume":"618","author":"Merghoub","year":"2023","journal-title":"Nature"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for NSCLC","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab vs chemotherapy in PD-L1\u2013high NSCLC","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab vs docetaxel in NSCLC","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1697505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:20:38Z","timestamp":1768206038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1697505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":195,"alternative-id":["10.3389\/fimmu.2025.1697505"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1697505","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1697505"}}